
AVIENCE
Avience Biomedicals Limited
- IPO Status
- Closed
- Open Date
- 18 Jun 2026
- Close Date
- 22 Jun 2026
IPO Details
- Min. Investment
- ₹2,49,600
- Price Band
- ₹196 - ₹208
- Lot Size
- 600 shares
- Issue Size
- ₹30 Cr
- Face Value
- 10
- IPO Doc
- —
Schedule
- IPO open18 Jun 2026
- IPO close date22 Jun 2026
- Allotment date23 Jun 2026
- Funds unblock or debit24 Jun 2026
- Listing date25 Jun 2026
Financial Performance
- Revenue
- Profit
FAQs
Avience Biomedicals Limited IPO is a SME IPO aggregating up to ₹30 Cr, with equity shares of face value ₹10 each. The shares are proposed to be listed on NSE.
The Avience Biomedicals Limited IPO opened on 18 Jun 2026 and closed on 22 Jun 2026. IPO Period: 18 Jun 2026 – 22 Jun 2026.
The price band for the Avience Biomedicals Limited IPO is ₹196 to ₹208 per share. Investors can bid within the specified price band, subject to the applicable IPO rules.
The minimum lot size is 600 shares. At the upper price band of ₹208, the minimum investment required is ₹2,49,600.
Particular Details Lot Size 600 shares Minimum Application 1,200 shares Price Band ₹196 – ₹208 Minimum Investment ₹2,49,600 Here is the timeline for the Avience Biomedicals Limited IPO:
IPO Event Date IPO Opens 18 Jun 2026 IPO Closes 22 Jun 2026 UPI Mandate Deadline 22 Jun 2026, 5:00 PM Basis of Allotment 23 Jun 2026 Refund Initiation 24 Jun 2026 Shares Credited 24 Jun 2026 Listing Date 25 Jun 2026 The basis of allotment for the Avience Biomedicals Limited IPO is expected to be finalised on 23 Jun 2026. Investors can check their allotment status through the registrar or relevant stock exchange website using their application details. Registrar: Skyline Financial Services.
The equity shares of Avience Biomedicals Limited are proposed to be listed on NSE. Proposed Listing Date: 25 Jun 2026.
The key financial performance of Avience Biomedicals Limited is:
Financial Year Revenue Profit FY24 ₹23.96 Cr ₹2.16 Cr FY25 ₹45.24 Cr ₹7.1 Cr FY26 ₹52.51 Cr ₹8.75 Cr Revenue CAGR: 48% | Profit CAGR: 101.3%. Figures are as disclosed in the company's offer documents.


